Clinical trial
Clinical Trial Phase IIB Randomized, Multicenter, of Continuation or Non Continuation With 6 Cycles of Temozolomide After the First 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.
NCT02209948 is registered in ClinicalTrials.gov with Grupo Español de Investigación en Neurooncología as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical Trial Phase IIB Randomized, Multicenter, of Continuation or Non Continuation With 6 Cycles of Temozolomide After the First 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.
- Lead sponsor
- Grupo Español de Investigación en Neurooncología
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 22, 2014
- Completion date
- June 14, 2019
- Enrollment
- 166 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.